European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading

MT Newswires Live
Sep 30

European equities traded in the US as American depositary receipts were tracking slightly higher Tuesday morning, rising 0.18% to 1,549.94 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies (DBVT) and semiconductor company Sequans Communications (SQNS), which rose 6.2% and 4% respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and biopharmaceutical company Genfit (GNFT), which were up 3.4% and 3% respectively.

The decliners from continental Europe were led by oil and gas company TotalEnergies (TTE) and biopharmaceutical company Cellectis (CLLS), which fell 2.2% and 2.1% respectively. They were followed by petroleum refiner Equinor (EQNR) and oil and gas company Eni (E), which were down 1.7% and 1.6% respectively.

From the UK and Ireland, the gainers were led by pharmaceutical company GSK (GSK) and biotech firm Autolus Therapeutics (AUTL), which increased 4.4% and 3.5% respectively. They were followed by pharmaceutical company AstraZeneca (AZN) and utilities company National Grid (NGG), which advanced 1.6% and 1.2% respectively.

The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biotech firm Trinity Biotech (TRIB), which dropped 4.4% and 1.9% respectively. They were followed by oil and gas company Shell (SHEL) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which lost 1.8% and 1.6% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10